Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216047 · ClinicalTrials.gov registry record · Phase 1
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
A Phase 1 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00216047: Clinical Trial Phase 1 study, sponsored by Hoosier Cancer Research Network.
NCT00216047 is a Phase 1 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00216047, a Phase 1 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in HER2-positive breast cancer. New therapeutics targeting VEGF and/or its receptors may enhance the efficacy of trastuzumab monotherapy. This trial will investigate the safety and efficacy of combined HER2 and VEGF inhibition.
Interventions
- DRUG Trastuzumab
- DRUG PTK787
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Why NCT00216047 stopped before completion
NCT00216047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00216047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00216047 about?
NCT00216047 is a clinical study titled "PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer". HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in HER2-positive breast cancer. New ther...
What is the current status of trial NCT00216047?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2005-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00216047?
The interventions under investigation include: Trastuzumab (DRUG), PTK787 (DRUG).
Who is sponsoring clinical trial NCT00216047?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00216047's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia